{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T13:13:30Z","timestamp":1790082810028,"version":"4.0.1"},"reference-count":43,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2011,4,1]],"date-time":"2011-04-01T00:00:00Z","timestamp":1301616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,4,1]],"date-time":"2011-04-01T00:00:00Z","timestamp":1301616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,4,10]],"date-time":"2015-04-10T00:00:00Z","timestamp":1428624000000},"content-version":"vor","delay-in-days":1470,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2011,4]]},"DOI":"10.1016\/j.bbmt.2010.04.017","type":"journal-article","created":{"date-parts":[[2010,5,11]],"date-time":"2010-05-11T08:02:22Z","timestamp":1273564942000},"page":"507-515","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":62,"title":["Efficacy, Safety, and Breakthrough Infections Associated with Standard Long-Term Posaconazole Antifungal Prophylaxis in Allogeneic Stem Cell Transplantation Recipients"],"prefix":"10.1016","volume":"17","author":[{"given":"Drew J.","family":"Winston","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy","family":"Bartoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary C.","family":"Territo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary J.","family":"Schiller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2010.04.017_bib1","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1086\/522189","article-title":"Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 study (Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne)","volume":"45","author":"Pagano","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bbmt.2010.04.017_bib2","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1086\/591969","article-title":"Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: biological risk factors for infection according to time alter transplantation","volume":"47","author":"Garcia-Vidal","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bbmt.2010.04.017_bib3","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1086\/595846","article-title":"Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of multicenter prospective antifungal therapy (PATH) alliance registry","volume":"48","author":"Neofytus","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bbmt.2010.04.017_bib4","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1086\/605665","article-title":"Prophylaxis and treatment of invasive fungal diseases in allogeneic stem cell transplantation: results of a consensus process by Gruppo Italiano Trapianto di Midollo Osseo (GITMO)","volume":"49","author":"Girmenia","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bbmt.2010.04.017_bib5","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1053\/bbmt.1999.v5.pm10371357","article-title":"Fungal infections after bone marrow transplant","volume":"5","author":"Wingard","year":"1999","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.04.017_bib6","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1056\/NEJM199203263261301","article-title":"A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation","volume":"326","author":"Goodman","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2010.04.017_bib7","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1093\/infdis\/171.6.1545","article-title":"Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation: a prospective, randomized double-blind study","author":"Slavin","year":"1995","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.bbmt.2010.04.017_bib8","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1086\/321805","article-title":"Centers for Disease Control and Prevention, Infectious Disease Society of America, American Society of Blood and Marrow Transplantation. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients","volume":"33","author":"Dykewicz","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bbmt.2010.04.017_bib9","doi-asserted-by":"crossref","first-page":"205","DOI":"10.7326\/0003-4819-138-9-200305060-00006","article-title":"Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients: a multicenter, randomized trial","volume":"138","author":"Winston","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.bbmt.2010.04.017_bib10","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1182\/blood-2003-08-2644","article-title":"Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants","volume":"103","author":"Marr","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.04.017_bib11","doi-asserted-by":"crossref","first-page":"55a","DOI":"10.1182\/blood.V110.11.163.163","article-title":"Results of a randomized double-blind trial of fluconazole vs voriconazole for the prevention of invasive fungal infections in 600 allogeneic blood and marrow transplant patients","volume":"110","author":"Wingard","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.04.017_bib12","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1182\/blood-2004-03-1025","article-title":"Elimination of Aspergillus infection in allogeneic stem cell transplant recipients with long-term itraconazole prophylaxis: prevention is better than treatment. [Letter]","volume":"104","author":"Winston","year":"2004","journal-title":"Blood"},{"issue":"Suppl 7","key":"10.1016\/j.bbmt.2010.04.017_bib13","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1469-0691.2006.01610.x","article-title":"Itraconazole vs fluconazole for antifungal prophylaxis in allogeneic stem-cell transplant patients","volume":"12","author":"Winston","year":"2006","journal-title":"Clin Microbial Infect"},{"key":"10.1016\/j.bbmt.2010.04.017_bib14","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1086\/422723","article-title":"Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis","volume":"39","author":"Siwek","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bbmt.2010.04.017_bib15","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1086\/428780","article-title":"Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases","volume":"191","author":"Kontoyiannis","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.bbmt.2010.04.017_bib16","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/sj.bmt.1705614","article-title":"Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem cell transplants or intensive chemotherapy","volume":"39","author":"Trifilio","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.04.017_bib17","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1128\/AAC.00163-06","article-title":"In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts","volume":"50","author":"Sabatelli","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bbmt.2010.04.017_bib18","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa061098","article-title":"Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease","volume":"356","author":"Ullmann","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2010.04.017_bib19","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1056\/NEJMoa061094","article-title":"Posaconazole vs fluconazole or itraconazole prophylaxis in patients with neutropenia","volume":"356","author":"Cornely","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2010.04.017_bib20","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1128\/AAC.00157-06","article-title":"Pharmacokinetics and safety of oral posaconazole in neutropenic stem cell transplant recipients","volume":"50","author":"Gubbins","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bbmt.2010.04.017_bib21","doi-asserted-by":"crossref","first-page":"5403","DOI":"10.1182\/blood-2007-11-121558","article-title":"Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled dose-ranging study","volume":"111","author":"Winston","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.04.017_bib22","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1086\/588660","volume":"46","author":"De Pauw","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bbmt.2010.04.017_bib23","series-title":"Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard\u2014third edition. Document M27-A3","author":"Clinical and Laboratory Standards Institute","year":"2008"},{"key":"10.1016\/j.bbmt.2010.04.017_bib24","series-title":"Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. Approved standard\u2014second edition. Document M38-A2","author":"Clinical and Laboratory Standards Institute","year":"2008"},{"key":"10.1016\/j.bbmt.2010.04.017_bib25","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jpba.2006.06.011","article-title":"A sensitive liquid chromatography and mass spectrometry method for the determination of posaconazole in human plasma","volume":"43","author":"Shen","year":"2007","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.bbmt.2010.04.017_bib26","doi-asserted-by":"crossref","first-page":"175","DOI":"10.6004\/jnccn.2008.0014","article-title":"Broad-spectrum antifungal prophylaxis in patients with cancer at high risk for invasive mold infections: point","volume":"6","author":"Gonzales","year":"2008","journal-title":"J Natl Comp Cancer Network"},{"key":"10.1016\/j.bbmt.2010.04.017_bib27","doi-asserted-by":"crossref","first-page":"183","DOI":"10.6004\/jnccn.2008.0015","article-title":"Broad-spectrum antifungal prophylaxis in patients with cancer at high risk for invasive mold infections: counterpoint","volume":"6","author":"Maertens","year":"2008","journal-title":"J Natl Comp Cancer Network"},{"key":"10.1016\/j.bbmt.2010.04.017_bib28","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3324\/haematol.11665","article-title":"Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies: recommendations of the infectious diseases working party of the German Society for Haematology and Oncology","volume":"94","author":"Cornely","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2010.04.017_bib29","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.bbmt.2009.06.019","article-title":"Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective","volume":"15","author":"Tomblyn","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.04.017_bib30","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1128\/AAC.01027-09","article-title":"Factors influencing pharmacokinetics of prophylactic posaconazole in patients undergoing allogeneic stem cell transplantation","volume":"54","author":"Kohl","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bbmt.2010.04.017_bib31","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1086\/422312","article-title":"Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation","volume":"39","author":"Van Burik","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bbmt.2010.04.017_bib32","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/bmt.2008.199","article-title":"Breakthrough Rhizopus infection on posaconazole prophylaxis following allogeneic stem cell transplantation","volume":"42","author":"Schlemmer","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.04.017_bib33","doi-asserted-by":"crossref","DOI":"10.1111\/j.1399-3062.2009.00479.x","article-title":"Breakthrough zygomycosis on posaconazole prophylaxis after allogeneic stem cell transplantation","author":"Mousset","year":"2009","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.bbmt.2010.04.017_bib34","doi-asserted-by":"crossref","first-page":"5026","DOI":"10.1128\/AAC.01031-09","article-title":"Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species","volume":"53","author":"Mann","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bbmt.2010.04.017_bib35","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1592\/phco.28.10.1223","article-title":"Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome","volume":"28","author":"Krishna","year":"2008","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.bbmt.2010.04.017_bib36","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1592\/phco.27.12.1627","article-title":"Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease","volume":"27","author":"Krishna","year":"2007","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.bbmt.2010.04.017_bib37","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1086\/508774","article-title":"Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial","volume":"44","author":"Walsh","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bbmt.2010.04.017_bib38","doi-asserted-by":"crossref","first-page":"5224","DOI":"10.1128\/AAC.00939-09","article-title":"Therapeutic drug monitoring of posaconazole: a monocentric study with 54 adults","volume":"53","author":"Lebeaux","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bbmt.2010.04.017_bib39","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1128\/AAC.01034-08","article-title":"Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers","volume":"53","author":"Krishna","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bbmt.2010.04.017_bib40","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1128\/AAC.01178-08","article-title":"Pharmacokinetics of posaconazole administered orally or by nasogastric tube in healthy volunteers","volume":"53","author":"Ashley","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bbmt.2010.04.017_bib41","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00240-09","article-title":"Posaconazole therapeutic drug monitoring: a reference laboratory experience","volume":"53","author":"Thompson","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bbmt.2010.04.017_bib42","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1182\/blood-2003-07-2512","article-title":"Cyclophosphamide metabolism is affected by azole antifungals","volume":"103","author":"Marr","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.04.017_bib43","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1086\/496927","article-title":"Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study","volume":"41","author":"Maertens","year":"2005","journal-title":"Clin Infect Dis"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879110001989?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879110001989?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:38:48Z","timestamp":1761057528000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879110001989"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4]]},"references-count":43,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["S1083879110001989"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2010.04.017","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2011,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy, Safety, and Breakthrough Infections Associated with Standard Long-Term Posaconazole Antifungal Prophylaxis in Allogeneic Stem Cell Transplantation Recipients","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2010.04.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}